Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Imipenem is a broad-spectrum carbapenem antibiotic belonging to the beta-lactam class of antimicrobial agents. Its chemical formula is C12H17N3O4S, and it is identified by the CAS number 66005-00-7. This potent compound is typically administered in combination with cilastatin sodium, an enzyme inhibitor that prevents renal degradation of imipenem by dehydropeptidase I, thereby preserving its therapeutic concentration in the body. The primary mechanism of action involves the inhibition of bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Imipenem demonstrates exceptional activity against a wide range of Gram-positive and Gram-negative bacteria, including many multidrug-resistant strains. It is particularly effective against organisms such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella species, and anaerobes like Bacteroides fragilis. Due to its stability against most beta-lactamases produced by resistant pathogens, it serves as a critical drug of last resort for severe, life-threatening infections where other antibiotics have failed or are ineffective. Common clinical indications include complicated intra-abdominal infections, gynecological infections, skin and soft tissue infections, bone and joint infections, and serious lower respiratory tract infections.
The drug is primarily administered intravenously due to poor oral bioavailability. While highly effective, its use requires careful monitoring for potential adverse effects, which may include gastrointestinal disturbances, seizures (especially in patients with central nervous system disorders or renal impairment), and hypersensitivity reactions. Resistance to imipenem can develop through the production of specific metallo-beta-lactamases or porin channel mutations, necessitating prudent stewardship to maintain its efficacy. As a cornerstone in modern antimicrobial therapy, imipenem remains indispensable in hospital settings for managing complex infections caused by resistant microbial flora, bridging the gap between traditional beta-lactams and newer synthetic agents. Its development marked a significant advancement in treating sepsis and nosocomial infections globally.